Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

Marie Skłodowska-Curie Action · Running

MMM Medicine Made to Measure.

Coordinator
Eberhard Karls Universitaet Tuebingen, Germany
Runs
1 October 2023 to 30 September 2027
Status
Running
EU funding
€2.2m
Total cost
—
Partners
23 organisations in 8 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101120256

What the project is doing

In the project's own words, from its summary on CORDIS.

Modern medicine seeks to personalize diagnosis and treatment to the needs of individual patients. This need is heightened in particular for those individual patients where no treatments are available – and where current standard treatment development paradigms exclude to generate such. The ultimate goal of Medicine made to Measure (MMM) is to go even beyond the latest genetic medicine approaches, implementing a novel paradigm of treatment development: the field of single patient tailored antisense oligonucleotide (ASO) treatments for patients with nano-rare disease mutations.

Specifically, MMM will develop core modules of a novel “out-of-the-box”, but still EMA-advised treatment development path for these patients - from omics-based theranostics, via preclinical target validation to innovative trial methodology and a pioneering ethical framework for individualised genetic therapies. MMM provides a unique opportunity for doctoral candidates to be involved in building - and to receive training - in all core modules needed for tailored ASO treatment in Europe.

This new scientific field requires a new generation of open-minded, technology-fluent and applications-oriented experts. MMM will help educate future drug development and translational experts in adopting and disseminating such a cross-specialty approach. Our idea for this innovative training network is built on our personal experience and understanding of the importance of single patient tailored genetic treatments in the years to come.

We propose a consortium of world-leading experts and partners that present with extended experience and relevant know-how in molecular biology, neurology, translational medicine, biochemistry, bioinformatics, philosophy, mathematics, regulatory science and engineering. Thus, MMM provides an exceptional platform to young, ambitious and talented researchers who like to engage in supporting the concept of single patient tailored treatments.

Topics

Who is involved

OrganisationCityCountryRole
Eberhard Karls Universitaet TuebingenTuebingenGermanyCoordinator
Bianogmp GmbHGeraGermanyParticipant
Cegat GmbHTubingenGermanyAssociatedpartner
Fitt - Institut Fur Technologietransfer an Der Hochschule Fur Technikund Wirtschaft Des Saarlandes Gemeinnutzige GmbHSaarbruckenGermanyAssociatedpartner
Grasshopper Films GbRTübingenGermanyAssociatedpartner
Ludwig-Maximilians-Universitaet MuenchenPlaneggGermanyParticipant
NMI Technologietransfer GmbHReutlingenGermanyAssociatedpartner
Technische Universitaet IlmenauIlmenauGermanyAssociatedpartner
Universitaetsklinikum EssenEssenGermanyAssociatedpartner
Universitatsklinikum HeidelbergHeidelbergGermanyParticipant
XNApharma GmbHGeraGermanyAssociatedpartner
Eurordis - Rare Diseases EuropeParisFranceAssociatedpartner
Biotalentum Tudasfejleszto KftGoedoelloHungaryParticipant
Magyar Agrar- Es Elettudomanyi EgyetemGodolloHungaryAssociatedpartner
Alma Mater Studiorum - Universita Di BolognaBolognaItalyAssociatedpartner
Mhealth Technologies SRLBolognaItalyParticipant
Academisch Ziekenhuis LeidenLeidenNetherlandsParticipant
Agentschap College Ter Beoordeling Van GeneesmiddelenUtrechtNetherlandsAssociatedpartner
Charles River Laboratoiries Den Bosch BV'S-HertogenboschNetherlandsAssociatedpartner
Astrazeneca ABSodertaeljeSwedenAssociatedpartner
Uppsala UniversitetUppsalaSwedenParticipant
The Chancellor Masters and Scholars of the University of CambridgeCambridgeUnited KingdomAssociatedpartner
N=1 Collaborative, Inc.BostonUnited StatesAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI